Table 4 Patients’ clinical and biological characteristics according to GenPhenReSa group at infliximab initiation. CRP, C-reactive protein. Non-parametric Kruskal-Wallis test
Characteristics | Group 1 (AO, N = 9) | Group 2 (OCCC, N = 21) | Group 3 (MSC, N = 10) | Group 4 (PLN, N = 9) | Group 5 (EP, N = 6) | ρ-value |
|---|---|---|---|---|---|---|
Age, mean (years, min-max) | 49.2 [32–79] | 49.1 [13–80] | 47.9 [28–70] | 51.3 [39–78] | 49.3 [40–69] | 0.9 |
Sex (male/female) | 4/5 | 11/10 | 3/7 | 7/2 | 2/4 | 0.27 |
Ethnicity | ||||||
Caucasian Maghrebis West-Indies | 3 (33) 1 (12) 5 (55) | 17 (81) 3 (14) 1 (5) | 9 (90) 0 (0) 1 (10) | 5 (55) 3 (33) 1 (12) | 5 (83) 1 (17) 0 (0) | 0.01 |
Median disease duration (months, IQR) | 36 [7.5–74] | 65 [14–188] | 49.5 [21.25–180] | 85 [30.5–121] | 15.5 [3.5–40] | 0.09 |
Lymphopenia CD4+count (×109/L) | 7 (77) 1.3 | 11 (52) 1.37 | 4 (40) 1.48 | 8 (89) 1.13 | 6 (100) 0.8 | 0.03 0.14 |
Increased gamma globulin levels | 3 (33) | 1 (5) | 2 (20) | 2 (22) | 1 (17) | 0.34 |
Inflammation with elevated CRP | 7 (77) | 8 (38) | 3 (33) | 4 (44) | 4 (67) | 0.18 |
Elevated angiotensin-converting enzyme | 3 (33) | 6 (28) | 2 (20) | 5 (55) | 2 (33) | 0.55 |
Median number of previous therapies (min-max) | 1 [0–2] | 2 [1–2.5] | 2 [1–4] | 2 [2–3] | 2 [0.75–3.25] | 0.22 |
Number of patients who required an increased dose of steroids | 6 (67) | 14 (67) | 2 (20) | 2 (22) | 2 (33) | 0.04 |
Median dose of oral steroids (mg/day, IQR) | 0 [0–8.75] | 9 [0–17.5] | 7.5 [0–16.25] | 15 [0–20] | 30 [3.75–51.25] | 0.18 |
Pulses of methylprednisolone | 2 (33) | 9 (43) | 1 (10) | 1 (12) | 3 (50) | 0.16 |
Concomitant immunosuppressant | 0 (0) | 4 (19) | 4 (40) | 1 (12) | 2 (33) | 0.21 |